Navigation Links
Neuron loss in schizophrenia and depression could be prevented with an antioxidant
Date:3/13/2013

Philadelphia, PA, March 13, 2013 Gamma-aminobutyric acid (GABA) deficits have been implicated in schizophrenia and depression. In schizophrenia, deficits have been particularly well-described for a subtype of GABA neuron, the parvalbumin fast-spiking interneurons. The activity of these neurons is critical for proper cognitive and emotional functioning.

It now appears that parvalbumin neurons are particularly vulnerable to oxidative stress, a factor that may emerge commonly in development, particularly in the context of psychiatric disorders like schizophrenia or bipolar disorder, where compromised mitochondrial function plays a role. parvalbumin neurons may be protected from this effect by N-acetylcysteine, also known as Mucomyst, a medication commonly prescribed to protect the liver against the toxic effects of acetaminophen (Tylenol) overdose, reports a new study in the current issue of Biological Psychiatry.

Dr. Kim Do and collaborators, from the Center for Psychiatric Neurosciences of Lausanne University in Switzerland, have worked many years on the hypothesis that one of the causes of schizophrenia is related to vulnerability genes/factors leading to oxidative stress. These oxidative stresses can be due to infections, inflammations, traumas or psychosocial stress occurring during typical brain development, meaning that at-risk subjects are particularly exposed during childhood and adolescence, but not once they reach adulthood.

Their study was performed with mice deficient in glutathione, a molecule essential for cellular protection against oxidations, leaving their neurons more exposed to the deleterious effects of oxidative stress. Under those conditions, they found that the parvalbumin neurons were impaired in the brains of mice that were stressed when they were young. These impairments persisted through their life. Interestingly, the same stresses applied to adults had no effect on their parvalbumin neurons.

Most strikingly, mice treated with the antioxidant N-acetylcysteine, from before birth and onwards, were fully protected against these negative consequences on parvalbumin neurons.

"These data highlight the need to develop novel therapeutic approaches based on antioxidant compounds such as N-acetylcysteine, which could be used preventively in young at-risk subjects," said Do. "To give an antioxidant from childhood on to carriers of a genetic vulnerability for schizophrenia could reduce the risk of emergence of the disease."

"This study raises the possibility that GABA neuronal deficits in psychiatric disorder may be preventable using a drug, N-acetylcysteine, which is quite safe to administer to humans," added Dr. John Krystal, Editor of Biological Psychiatry.


'/>"/>

Contact: Rhiannon Bugno
Biol.Psych@utsouthwestern.edu
214-648-0880
Elsevier
Source:Eurekalert

Related medicine news :

1. Improper protein digestion in neurons identified as a cause of familial Parkinsons
2. Lack of protein Sp2 disrupts neuron creation in brain
3. Protein identified that can disrupt embryonic brain development and neuron migration
4. Hunting neuron killers in Alzheimers and TBI
5. Protein build-up leads to neurons misfiring
6. Neurons derived from cord blood cells may represent new therapeutic option
7. Link between brain insulin resistance, neuronal stress in worsening Alzheimers disease
8. Neurons that control overeating also drive appetite for cocaine
9. Researchers restore neuron function to brains damaged by Huntingtons disease
10. Neuron-nourishing cells appear to retaliate in Alzheimers
11. Chronic cocaine use triggers changes in brains neuron structure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology: